Pearl vs Overjet vs VideaHealth: Direct Comparison for 2026

Pearl, Overjet, and VideaHealth dominate conversations about dental AI adoption, but they solve different problems. Understanding those differences matters more than comparing feature lists.

What Each Platform Actually Does

Pearl focuses on clinical diagnostics. The platform uses AI to flag potential caries, periodontal disease, and other pathologies from intraoral imaging. Practices deploy Pearl primarily as a second reader—a safety net during exam workflows. Integration happens at the chair level, which means hygienists and dentists see flagged areas in real time.

Overjet centers on insurance claims and billing workflows. The platform automates predetermination requests, identifies missing documentation, and flags claim denials before submission. It's designed to reduce admin friction and accelerate reimbursement cycles. Overjet works downstream from clinical capture rather than in the clinical environment itself.

VideaHealth builds patient engagement and practice growth infrastructure. The platform combines patient communication automation, appointment optimization, and treatment acceptance tracking. It's operating-system-level software—the kind practices layer across multiple clinical and business functions.

The Real Tradeoffs

When you're choosing between these, you're not actually choosing a single platform. You're choosing a primary problem to solve.

Pearl makes sense if your practice has clinical consistency issues or high associate turnover. You get immediate risk mitigation in the diagnostic phase. The cost-to-value equation works when clinical staff have variable experience levels or when you want to reduce missed pathology liability. But Pearl doesn't reduce scheduling chaos or improve your insurance approval rates. It's narrowly excellent at one thing.

Overjet pays for itself through claims acceleration and denial reduction. A typical practice might see 15–20% of claims denied initially. Overjet's documentation flagging and predetermination automation can recover 3–5% of annual revenue in practices doing $2M+ annually. That's measurable, auditable ROI. However, Overjet doesn't touch clinical workflows or patient experience. If your problem is scheduling delays or treatment acceptance rates, Overjet won't solve it.

VideaHealth addresses operational drag points that compound across a year. A 15-minute improvement in daily scheduling efficiency, multiplied across 250 treatment days, equals 62.5 hours recovered annually per practice location. Patient no-show rates often drop 8–12% when practices activate VideaHealth's appointment reminders and confirmations. The value is real but diffuse—you're buying incremental gains across multiple areas.

Integration Reality for 2026

All three platforms claim integration with major practice management systems. Pearl integrates with imaging workflow (CBCT, intraoral cameras). Overjet connects to claim submission pipelines and insurance verification. VideaHealth pulls appointment and patient data from your PMS.

But integration depth matters. Pearl requires practice managers to trust AI findings enough to act on them—if clinicians ignore flags consistently, the platform becomes liability without benefit. Overjet's value depends on your claim denial patterns actually matching what the platform targets. VideaHealth's value depends on your baseline no-show and acceptance rates being improvable through better communication.

In 2026, the integration question isn't "does it connect"—it's "does it connect in a way that changes your bottleneck."

Which One Should You Actually Buy?

Start by diagnosing your practice's constraint.

If clinical safety and consistency are your constraint, Pearl justifies itself. The cost is typically $200–500/month plus per-exam licensing. Budget for staff training and workflow adjustment.

If reimbursement velocity and claim accuracy are constraints, Overjet's 3–5% revenue recovery ROI is hard to argue against. Implementation is faster than clinical tools because it doesn't require chairside behavior change.

If appointment no-shows, treatment acceptance, or patient communication are constraints, VideaHealth's operational leverage works. You're buying throughput improvement rather than risk mitigation.

The practices achieving real traction in 2026 aren't choosing one. They're deploying all three—but sequentially, starting with the constraint that costs them the most margin daily.

Measure your baseline before buying any of them. Measure again six months in. That gap is the only number that matters.